Fulcrum Therapeutics, Inc. (FULC) Stock Score, Valuation & Financial Research

Fulcrum Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for FULC

Fulcrum Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.70. These figures are a research snapshot, not a buy or sell recommendation.

What Fulcrum Therapeutics, Inc. does

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetically defined diseases. The company currently generates no product revenue and relies on capital raises and potential future milestone or royalty payments from collaborative research and development agreements to fund its operations.

Products and services

  • The company's primary product candidate is pociredir, an oral small molecule inhibitor of fetal hemoglobin, currently in clinical development for the treatment of sickle cell disease.

Brands and product families

  • Pociredir — Lead clinical-stage product candidate for sickle cell disease. Source

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug substance, with specific suppliers remaining unnamed. Source

Competitors and product-market comparisons

  • CRISPR Therapeutics — Competes in the development of therapeutic approaches for sickle cell disease. Source

Business strengths to evaluate

  • Proprietary product engine focused on gene regulation Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a limited number of product candidates Source

Sources: Company research source · CRISPR Therapeutics

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

FULC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.70
Market capitalization:
282.3M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -85M
Free cash flow:
USD -60.38M
Cash:
USD 48.47M
Total debt:
USD 5.28M
EPS:
USD -1.21

What stands out

  • Free cash flow is USD -60.38M, negative for the stored period.
  • The balance sheet shows USD 48.47M of cash versus USD 5.28M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 43.19M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for FULC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can FULC fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is FULC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for FULC to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of FULC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research FULC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.